# Emergent BioSolutions

supplies anthrax vaccine and smallpox medical countermeasures under direct government delivery contracts, including a contract with the US Department of War and international government partners.


Source: https://bioecon.ru/companies/emergent-biosolutions/
Updated: 2026-08-15

- Страна: United States
- Тикер: NYSE:EBS

## Проверяемые факты

| Факт | Значение | Источник |
| --- | --- | --- |
| Выручка | $743 миллиона за 2025 год | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| Численность | 850 сотрудников | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| Финансирование | изменение контракта на $52.7 миллиона (июнь 2026) по ACAM2000 | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| Финансирование | Изменение контракта на $30 миллионов (сентябрь 2025 года) для CYFENDUS | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| Финансирование | Контракт на $54 млн (март 2026 г.) на CNJ-016 | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award |
| Финансирование | Пятилетний контракт на $235.8 млн (2024) на BioThrax | https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply |
| Производственная площадка | Виннипег, Канада | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Производственная площадка | Лансинг, Мичиган | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Производственная площадка | Балтимор, Мэриленд (Bayview и Camden) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview, https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Производственная площадка | Кантон, Массачусетс | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Производственная площадка | Хаттисберг, Миссисипи | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Производственная площадка | Роквилл, Мэриленд | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| Сертификация | статус No Action Indicated (NAI) для объекта Baltimore Bayview (март 2024) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview |
| Сертификация | Статус Voluntary Action Indicated (VAI) для объекта в Камдене (октябрь 2023) | https://www.sec.gov/Archives/edgar/data/1367644/000136764423000169/ebs-20231005.htm |
| Регуляторное одобрение | Одобрение FDA для CYFENDUS (июль 2023) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-us-fda-approval-drug-product, https://investors.emergentbiosolutions.com/node/23881/pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| Регуляторное одобрение | одобрение FDA sBLA для производства раксибакумаба в Виннипеге (декабрь 2025 года) | https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |

Независимые источники: fiercepharma.com, sec.gov, synapse.patsnap.com

## Технологии

- [Оборонная биоэкономика](https://bioecon.ru/technology/defense-bioeconomy/)